Survodutide (Dual Glucagon/GLP-1)
$310.00Survodutide is a cutting-edge dual glucagon and GLP-1 receptor agonist that boosts hepatic energy expenditure and fat burning while eliminating cravings.
Available: 2.4mg Weekly, 4.8mg Weekly
In Stock (40 available)
Why Choose Survodutide?
Unique glucagon component stimulates liver fat clearance (MASH/NASH improvement) alongside aggressive body weight reduction.
How to Use
Administer once weekly via subcutaneous injection following titration guidelines.
Safety Information
For medically guided metabolic and weight management programs.
Potential Side Effects
Transient nausea, changes in bowel habits, and increased initial thermogenesis.
Product Facts
| Generic Name | Survodutide (BI 456906) |
| Brand Name | Survodutide |
| Type of Medication | Dual Glucagon / GLP-1 Receptor Agonist |
| FDA Approval Date | March 1, 2024 |
| Indications | Dual agonist targeted for obesity treatment and metabolic dysfunction-associated steatohepatitis (MASH/NASH). |
| Dosage Forms | Subcutaneous solution in prefilled injector pen (2.4 mg, 4.8 mg) |
| Administration | Once weekly subcutaneous injection |
| Special Precautions | Simultaneous glucagon receptor activation stimulates hepatic fatty acid oxidation while GLP-1 manages satiety. |
| Drug Interactions | Gastrointestinal motility delays oral drug transit. |
| Use in Specific Populations | Adult use under supervised metabolic protocols. |
| Prescription | Prescription Required |
| Manufacturer | Boehringer Ingelheim / Zealand Pharma |
How to Buy
Select your desired concentration and proceed with our encrypted checkout.